Allergy Therapeutics (Allergy Therapeutics) Liabilities-to-Assets : 0.62 (As of Dec. 2023)

Allergy Therapeutics Liabilities-to-Assets Chart

Allergy Therapeutics Annual Data
	Trend	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
Liabilities-to-Assets		Get a 7-Day Free Trial					0.45	0.49	0.45	0.48	0.97

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Liabilities-to-Assets	Get a 7-Day Free Trial															0.40	0.48	0.47	0.97	0.62

Competitive Comparison of Allergy Therapeutics's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Liabilities-to-Assets falls into.

Allergy Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Allergy Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Allergy Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics  (OTCPK:AGYTF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Allergy Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (Allergy Therapeutics) Business Description